Manufacturer for Doxycycline Mono Hyclate 100mg - Dabigatran Etexilate Mesylate – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

abide by the contract", conforms on the market requirement, joins within the market competition by its superior quality likewise as provides far more comprehensive and great company for shoppers to let them develop into huge winner. The pursue on the corporation, is definitely the clients' gratification for Daclatasvir Plus Sofosbuvir, Pregabalin Manufacturer, Doxycycline Mono For Tooth Infection, We warmly welcome customers from all over the world for any kind of cooperation with us to build a mutual benefit future. We are devoting ourselves wholeheartedly to offer customers the best service.
Manufacturer for Doxycycline Mono Hyclate 100mg - Dabigatran Etexilate Mesylate – CPF Detail:

Description

Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran. Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.

Background

Description: IC50 Value: 4.5nM (Ki); 10nM(Thrombin-induced platelet aggregation) [1] Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally active prodrug,dabigatran etexilate. in vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1]. in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2]. Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1

Storage

Powder

-20°C

3 years
 

4°C

2 years
In solvent

-80°C

6 months
 

-20°C

1 month

Clinical Trial

NCT Number Sponsor Condition Start Date

Phase

NCT02170792 Boehringer Ingelheim Healthy February 2001

Phase 1

NCT02170974 Boehringer Ingelheim Healthy July 2004

Phase 1

NCT02170831 Boehringer Ingelheim Healthy May 1999

Phase 1

NCT02170805 Boehringer Ingelheim Healthy April 2001

Phase 1

NCT02170610 Boehringer Ingelheim Healthy March 2002

Phase 1

NCT02170909 Boehringer Ingelheim Healthy December 2004

Phase 1

NCT02171000 Boehringer Ingelheim Healthy April 2005

Phase 1

NCT02170844 Boehringer Ingelheim Healthy June 2004

Phase 1

NCT02170584 Boehringer Ingelheim Healthy January 2001

Phase 1

NCT02170935 Boehringer Ingelheim Venous Thromboembolism April 2002

Phase 2

NCT02170636 Boehringer Ingelheim Healthy January 2002

Phase 1

NCT02170766 Boehringer Ingelheim Healthy October 2000

Phase 1

NCT02171442 Boehringer Ingelheim Healthy April 2002

Phase 1

NCT02170896 Boehringer Ingelheim Healthy October 2001

Phase 1

NCT02173730 Boehringer Ingelheim Healthy November 2002

Phase 1

NCT02170623 Boehringer Ingelheim Healthy February 2002

Phase 1

NCT02170116 Boehringer Ingelheim Healthy November 1998

Phase 1

NCT02170597 Boehringer Ingelheim Healthy August 2003

Phase 1

NCT01225822 Boehringer Ingelheim Venous Thromboembolism November 2002

Phase 2

NCT02170701 Boehringer Ingelheim Venous Thromboembolism October 2000

Phase 2

NCT02170740 Boehringer Ingelheim Healthy November 1999

Phase 1

NCT02170922 Boehringer Ingelheim Healthy July 1999

Phase 1

Chemical structure

Dabigatran Etexilate Mesylate

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation


Product detail pictures:

Manufacturer for Doxycycline Mono Hyclate 100mg - Dabigatran Etexilate Mesylate  – CPF detail pictures


Related Product Guide:

We are committed to providing easy,time-saving and money-saving one-stop purchasing service of consumer for Manufacturer for Doxycycline Mono Hyclate 100mg - Dabigatran Etexilate Mesylate – CPF , The product will supply to all over the world, such as: venezuela, Tanzania, Cairo, Our company abides by the management idea of "keep innovation, pursue excellence". On the basis of assuring the advantages of existing merchandise, we continuously strengthen and extend product development. Our company insists on innovation to promote the sustainable development of enterprise, and make us become the domestic high-quality suppliers.
  • The after-sale warranty service is timely and thoughtful, encounter problems can be resolved very quickly, we feel reliable and secure.
    5 Stars By Nicci Hackner from Israel - 2018.09.19 18:37
    Company director has very rich management experience and strict attitude, sales staff are warm and cheerful, technical staff are professional and responsible,so we have no worry about product,a nice manufacturer.
    5 Stars By Rebecca from Poland - 2018.12.14 15:26
    Write your message here and send it to us